GlassScriptPhysician profile
Kashif Jafri
NPI 1598025884
$8,682.07
in general payments reported to CMS, 2019-2025
29 companies · $1,968 in 2025
The $1,968 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $513 · 2020: $76.96 · 2021: $658 · 2022: $1,356 · 2023: $2,055 · 2024: $2,056 · 2025: $1,968.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,955 · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,955.26 |
| Education | $123.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,536.54 | 2020-2025 | |
| Amgen INC. | $1,135.53 | 2019-2025 | Enbrel, Tavneos, Krystexxa |
| Novartis Pharmaceuticals Corporation | $1,022.80 | 2019-2025 | |
| Pfizer INC. | $725.92 | 2019-2025 | |
| Ucb, INC. | $660.80 | 2021-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $648.69 | 2019-2025 | Tremfya, Simponi Aria |
| Astrazeneca Pharmaceuticals LP | $574.17 | 2022-2025 | Saphnelo, Fasenra |
| Glaxosmithkline, LLC. | $472.02 | 2019-2025 | Benlysta, Nucala |
| Horizon Therapeutics Plc | $285.54 | 2021-2023 | Krystexxa |
| Lilly USA, LLC | $224.54 | 2019-2024 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $147.54 | 2021-2025 | Orencia |
| Aurinia Pharma U.S., INC. | $146.83 | 2021-2025 | Lupkynis |
| Celgene Corporation | $141.03 | 2019 | |
| Genzyme Corporation | $132.36 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $109.74 | 2022-2024 | Strensiq |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $95.77 | 2023-2025 | Renflexis, Hadlima |
| Sobi, INC | $87.83 | 2023-2025 | |
| Genentech USA, INC. | $85.04 | 2021-2023 | Actemra |
| Radius Health, INC. | $77.19 | 2023-2025 | Tymlos |
| Biocon Biologics INC | $76.84 | 2024-2025 | Hulio, Yesintek |
| Sandoz INC. | $57.32 | 2023-2024 | Hyrimoz |
| Ani Pharmaceuticals, INC. | $48.70 | 2025 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.08 | 2023 | Ofev, Cyltezo |
| Octapharma USA, INC. | $34.20 | 2022-2023 | Octagam Immune Globulin (Human) |
| Invivyd INC | $31.81 | 2025 | Pemgarda |
| Mallinckrodt Hospital Products INC. | $25.84 | 2021 | |
| Hikma Pharmaceuticals USA | $21.67 | 2019 | |
| Janssen Scientific Affairs, LLC | $15.38 | 2020 | |
| Kiniksa Pharmaceuticals, LTD. | $14.35 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kashif Jafri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.